Core Insights - The new National Medical Insurance Directory has added 114 new drugs, surpassing last year's addition of 91, with 50 being first-class innovative drugs, achieving an overall success rate of 88%, an improvement from 76% in 2024 [1][2] Group 1: New Drug Additions - The total number of drugs in the directory has increased to 3,253, significantly enhancing coverage for key areas such as oncology and chronic diseases [2] - The directory includes 38 global innovative drugs and 50 first-class innovative drugs, marking a historical high for new additions [2] - Notable inclusions are the first globally approved red blood cell maturation agent, Rotecip, for treating lower-risk myelodysplastic syndromes, and the first domestically developed IL-4Rα antibody drug, Kangyueda, for multiple indications [3][4] Group 2: Oncology Innovations - Several innovative oncology drugs have been added, including Tagolizumab, the first PD-L1 monoclonal antibody approved for nasopharyngeal carcinoma, and non-covalent BTK inhibitor, Jebatib, for relapsed mantle cell lymphoma [4][5][6] - ADCs (antibody-drug conjugates) have gained attention, with new entries like Lukanasatuzumab and Ruikangquzuzumab, targeting advanced breast cancer and non-small cell lung cancer [7][8] Group 3: Chronic Disease Treatments - The directory has included innovative drugs for chronic diseases, such as Novartis' PCSK9 mRNA interference drug for cholesterol management, addressing patients who cannot reach LDL-C targets [14] - AstraZeneca's biologic drug Benralizumab for severe eosinophilic asthma has also been added, providing targeted treatment options for patients [15][16] Group 4: Influenza Treatments - The new directory has incorporated two domestic antiviral drugs for influenza, Masurashave and Angladiv, which have shown promising clinical results in reducing symptoms and viral load [17]

Core Viewpoint - The National Healthcare Security Administration (NHSA) has released the new basic medical insurance drug list for 2025, which will take effect on January 1, 2026, leading to a significant increase in the success rate of new drug negotiations, particularly for innovative drugs with high clinical value [1][2]. Group 1: New Drug Negotiation Success - The success rate for new drug negotiations in 2025 has significantly improved to 88%, up from 76% in 2024, with 114 new drugs added to the national medical insurance drug list, including 50 Class 1 innovative drugs [2][3]. - The total number of drugs in the national medical insurance drug list has increased to 3,253, enhancing coverage for critical areas such as cancer, chronic diseases, mental health, rare diseases, and pediatric medications [2]. Group 2: Unique Drug Inclusion - Among the 114 newly added drugs, 105 are unique varieties, representing 92.11% of the total, including 98 Western medicines and 7 traditional Chinese medicines [3]. - The inclusion of unique traditional Chinese medicines from companies like China Resources Sanjiu, Yiling Pharmaceutical, and others indicates a balanced representation in the new drug list [3]. Group 3: Market Potential and Growth - The inclusion of 116 drugs in the latest negotiation, particularly 11 new drugs from Heng Rui Medicine and others, is expected to lead to rapid market share growth and product volume increase due to their entry into the medical insurance directory [4][5]. - The negotiation also included new mechanism drugs, such as antibody-drug conjugates and small nucleic acid siRNA drugs, which are anticipated to drive market penetration and accessibility [5]. Group 4: Commercial Health Insurance Directory - The first commercial health insurance innovative drug directory saw intense competition, with 121 candidates but only 24 entering negotiations, resulting in 19 drugs being successfully included [6]. - The directory covers critical diseases such as Alzheimer's and multiple myeloma, with a balanced mix of imported and domestic drugs [6]. Group 5: Investment Recommendations - Companies with a significant number of innovative drugs included in the new medical insurance directory, such as Heng Rui Medicine, BeiGene, and others, are recommended for investment [9]. - Potential growth in traditional Chinese medicine products included in the new directory, such as those from China Resources Sanjiu and Yiling Pharmaceutical, is also highlighted [9].

Core Viewpoint - 康诺亚-B (02162) shares rose over 4% following the announcement that its self-developed drug 康悦达® (司普奇拜单抗注射液) has been included in the National Basic Medical Insurance Drug List for 2025, effective from January 1, 2026 [1]. Group 1: Company Developments - 康诺亚 announced that its drug 康悦达® (司普奇拜单抗) is the first domestically developed IL-4Rα humanized monoclonal antibody approved for market, targeting type 2 inflammatory diseases through dual blockade of the IL-4/IL-13 signaling pathway [1]. - The drug has received approval for three indications: moderate to severe atopic dermatitis in adults inadequately controlled by topical medications, chronic rhinosinusitis with nasal polyps inadequately controlled by corticosteroids and/or surgery, and moderate to severe seasonal allergic rhinitis in adults inadequately controlled by nasal corticosteroids combined with antihistamines [1]. Group 2: Market Impact - Following the announcement, 康诺亚-B's stock price increased by 4.23%, reaching 61.6 HKD, with a trading volume of 1.3244 million HKD [1].

每经AI快讯，康诺亚-B(02162.HK)高开逾4%，截至发稿涨4.23%，报61.6港元，成交额132.44万港元。 （文章来源：每日经济新闻） ...

Core Viewpoint - 康诺亚-B's stock price increased by over 4% following the announcement of its drug 康悦达® being included in the National Basic Medical Insurance Drug List for 2025, effective from January 1, 2026 [1] Company Summary - 康诺亚-B's stock rose 4.23% to HKD 61.6 with a trading volume of HKD 1.3244 million [1] - The company announced that its self-developed Class 1 new drug 康悦达® (司普奇拜单抗 injection) has been included in the National Basic Medical Insurance Drug List [1] - 康悦达® is the first domestically developed and approved IL-4Rα humanized monoclonal antibody in China, targeting the dual blockade of IL-4/IL-13 signaling pathways to precisely inhibit the progression of type 2 inflammatory diseases [1] Drug Indications - 康悦达® has received approval for three indications: 1. Moderate to severe atopic dermatitis in adults inadequately controlled by topical medications 2. Chronic rhinosinusitis with nasal polyps inadequately controlled by corticosteroids and/or surgery 3. Moderate to severe seasonal allergic rhinitis in adults inadequately controlled by intranasal corticosteroids combined with antihistamines [1] - All three indications have been included in the updated National Basic Medical Insurance Drug List [1]

Core Viewpoint - 康诺亚-B's stock price increased by over 4% following the announcement that its self-developed drug, 康悦达 (司普奇拜单抗), has been included in the National Basic Medical Insurance Drug List for 2025, effective from January 1, 2026 [1] Group 1: Company Developments - 康诺亚 announced that 康悦达 (司普奇拜单抗) is the first domestically developed IL-4Rα humanized monoclonal antibody approved for market, targeting type 2 inflammatory diseases through dual blockade of the IL-4/IL-13 signaling pathway [1] - 康悦达 has received approval for three indications: moderate to severe atopic dermatitis in adults inadequately controlled by topical medications, chronic rhinosinusitis with nasal polyps inadequately controlled by corticosteroids and/or surgery, and moderate to severe seasonal allergic rhinitis in adults inadequately controlled by nasal corticosteroids combined with antihistamines [1] Group 2: Market Impact - Following the announcement, 康诺亚-B's stock rose by 4.23%, reaching a price of 61.6 HKD, with a trading volume of 1.3244 million HKD [1]

Core Insights - The 2025 National Medical Insurance Directory and the first Commercial Health Insurance Innovative Drug Directory were announced, marking a significant development in the pharmaceutical industry [1][3][10] - A total of 114 new drugs were added to the National Medical Insurance Directory, including 50 innovative drugs, which is expected to enhance patient access and support sustainable investment in drug development [1][2][3] National Medical Insurance Directory - The 2025 National Medical Insurance Directory includes 114 new drugs, with 50 classified as innovative drugs, such as Tislelizumab and domestic ADC drugs [1][3] - Companies like Kelun-Biotech and Kangnuo have successfully included their innovative drugs in the directory, reflecting strong government support for domestic innovation [3][4] - The total number of drugs in the National Medical Insurance Directory has increased to 3,253, with significant improvements in coverage for critical areas like oncology and chronic diseases [5][6] Commercial Health Insurance Innovative Drug Directory - The newly introduced Commercial Health Insurance Innovative Drug Directory includes five CAR-T cell therapies and several high-cost drugs for rare diseases, enhancing accessibility for patients [1][6][8] - The directory allows innovative drug companies to explore new payment channels outside of traditional medical insurance, potentially increasing patient access to high-value therapies [11][12] - The pricing for drugs in the Commercial Health Insurance Directory is expected to be more flexible, allowing for negotiations between companies and insurers, which could lead to better affordability for patients [8][12] Industry Impact - The introduction of the Commercial Health Insurance Innovative Drug Directory is seen as a milestone for improving drug accessibility and affordability, particularly for high-cost therapies [7][9][12] - The past decade has witnessed significant growth in China's innovative drug sector, with the new directory marking a pivotal moment in the industry's evolution [10][11] - The dual-track payment framework established by the National Medical Insurance and Commercial Health Insurance is expected to foster a more robust ecosystem for drug research and application in China [12]

Core Points - The 2025 National Medical Insurance Directory has added 114 new drugs, including 50 innovative drugs, which will significantly enhance patient access to essential medications [1][3][6] - The introduction of the Commercial Health Insurance Innovative Drug Directory marks a pivotal moment for innovative drug accessibility, allowing companies to explore new payment channels beyond traditional insurance [12][13] - The overall number of drugs in the National Medical Insurance Directory has increased to 3,253, with a notable focus on critical areas such as oncology, chronic diseases, and rare diseases [6][11] Group 1: National Medical Insurance Directory - The 2025 National Medical Insurance Directory includes 114 new drugs, with 50 classified as innovative drugs, such as Tislelizumab and domestic ADCs [1][3] - The directory aims to bridge gaps in basic medical insurance coverage for major diseases like triple-negative breast cancer and lung cancer [3][4] - The total number of drugs in the National Medical Insurance Directory has risen to 3,253, enhancing coverage for key disease areas [6] Group 2: Commercial Health Insurance Innovative Drug Directory - The Commercial Health Insurance Innovative Drug Directory includes five CAR-T cell therapies and two Alzheimer's disease drugs, addressing previously limited access due to high costs [1][7] - The directory allows innovative drug companies to seek new payment avenues, enhancing the affordability and accessibility of high-value drugs [12][13] - The introduction of this directory is seen as a significant milestone in improving patient access to innovative therapies [8][9] Group 3: Industry Impact and Future Outlook - The past decade has seen a surge in China's innovative drug development, with the 2025 directory marking a new phase in business development for the industry [11] - The dual-track payment framework of basic insurance and commercial insurance is expected to stimulate the market for innovative drugs [13] - Companies are encouraged to collaborate with insurance providers to enhance patient coverage and awareness of health insurance options [12][13]

Core Viewpoint - The company 康诺亚 has announced that its self-developed drug 康悦达 (Siplizumab Injection) has been included in the National Medical Insurance Drug List for 2025, effective from January 1, 2026, marking a significant milestone for the company and the industry [1] Group 1: Drug Development and Approval - 康悦达 is the first IL-4Rα antibody drug independently developed and approved for market in China [1] - The drug has received breakthrough therapy designation and priority review, supported by the national "13th Five-Year Plan" for major new drug creation [1] - 康悦达 has been approved for three indications: moderate to severe atopic dermatitis inadequately controlled by topical treatments, chronic sinusitis with nasal polyps inadequately controlled by corticosteroids and/or surgery, and moderate to severe seasonal allergic rhinitis inadequately controlled by nasal corticosteroids combined with antihistamines [1] Group 2: Strategic Vision and Commitment - The CEO of 康诺亚, Dr. Chen Bo, emphasized the company's commitment to "true innovation" and addressing unmet clinical needs [1] - The company aims to develop more globally competitive innovative drugs to benefit patients in China and worldwide, contributing to the improvement of public health and the high-quality development of the pharmaceutical industry [1]

Core Insights - The 2025 National Medical Insurance Directory has added 114 new drugs, including 50 innovative drugs, which will significantly enhance patient access to essential medications [1][3][6] - The introduction of the Commercial Health Insurance Innovative Drug Directory marks a pivotal moment for the pharmaceutical industry, allowing for new payment channels beyond traditional insurance [11][12] Summary by Sections National Medical Insurance Directory - The 2025 National Medical Insurance Directory includes 114 new drugs, with 50 classified as innovative drugs, such as Tislelizumab and domestic ADCs [1][3] - The total number of drugs in the National Medical Insurance Directory has increased to 3,253, with significant improvements in coverage for critical areas like oncology and rare diseases [6] Commercial Health Insurance Innovative Drug Directory - The Commercial Health Insurance Innovative Drug Directory features five CAR-T cell therapies and two imported Alzheimer's drugs, addressing previously limited access due to high costs [1][7] - The directory aims to enhance the accessibility of high-value innovative drugs, with a focus on improving patient affordability [9][10] Industry Impact - The inclusion of innovative drugs in the National Medical Insurance Directory is expected to accelerate the transition from laboratory to patient access, providing crucial support for sustainable investment in pharmaceutical R&D [2][4] - The launch of the Commercial Health Insurance Innovative Drug Directory allows pharmaceutical companies to explore new payment avenues, fostering a dual-track pricing system that recognizes the value of innovative therapies [12] Company Responses - Companies like WuXi AppTec and CanSino Biologics have expressed optimism about the new directories, highlighting the government's support for domestic innovation and the potential for improved patient outcomes [4][5][11] - The introduction of the directories has prompted companies to collaborate closely with insurance providers to ensure effective implementation and patient access [12]